Overview

Study to Evaluate the Safety of SP-104

Status:
Recruiting
Trial end date:
2021-12-20
Target enrollment:
Participant gender:
Summary
Evaluate the safety and tolerability of 3-day repeat-dose of SP-104 compared to naltrexone hydrochloride immediate release.
Phase:
Phase 1
Details
Lead Sponsor:
Scilex Pharmaceuticals, Inc.
Treatments:
Naltrexone